Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -44.60% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.27 |
| Price-to-Book | 2.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.02M |
| Float | $19.98M |
| % Insiders | 18.99% |
| % Institutions | 71.00% |
Volatility is currently contracting
NEW YORK, July 20, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders. The investigation seeks to determine whether AN2 Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi. Key findings from the two studies: In NHPs with naturally acquire.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics we.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. “This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This pr.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANTX and any ticker you trade — then tracks every position and per-strategy win rate.
